Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Phase 2

Withdrawn

• Conditions: Alzheimer Disease
• Interventions: Drug: Lemborexant 25 mg; Drug: Placebo

• Registration Number: NCT05728736
• Lead Sponsor: Brendan Lucey

Brief Summary

This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers

Detailed Description

This study will determine the acute effect of lemborexant on CNS tau phosphorylation and other Alzheimer's disease biomarkers in individuals with poor sleep quality.

Study Timeline

• Study First Submitted: 2023-02-05
• Study First Submitted QC: 2023-02-05
• Study First Posted: 2023-02-15
• Study Start: 2023-03-01
• Primary Completion: 2023-09-27
• Study Completion: 2023-10-04
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-03
• Last Update Posted: 2023-11-08

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Age 60-80 years
• Any sex
• Any race/ethnicity
• Mini-Mental Status Examination score (MMSE) ≥ 27
• Positive plasma amyloid-beta test (i.e., amyloid-positive)
• Pittsburgh Sleep Quality Index >5

Exclusion Criteria

• Cognitive impairment as determined by history of MMSE < 27
• Inability to speak or understand English
• Any sleep disorders other than insomnia
• No history of moderate-to-severe sleep-disordered breathing and STOP-Bang score > 5
• History or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders
• No more than mild sleep apnea (AHI <16) on PSG
• Sleep schedule outside the range of bedtime 22:00-midnight
• Contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery)
• Cardiovascular disease requiring medication except for controlled hypertension (PI discretion)
• Stroke
• Hepatic or renal impairment
• Pulmonary disease (PI discretion)
• Type 1 diabetes
• HIV or AIDS
• Neurologic or psychiatric disorder requiring medication (PI discretion)
• Suicidal ideations
• Alcohol, tobacco or marijuana use (PI discretion)
• Use of sedating medications (PI discretion)
• Inability to get out of bed independently
• In the opinion of the investigator, the participant should be excluded due to an abnormal physical examination.
• Current pregnancy
• Body Mass Index >35
• History of migraines (PI discretion)
• History of drug abuse in the last 6 months
• History or presence of any clinically significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the PI participant is not a good candidate.
• Urinary or fecal incontinence
• Concurrently enrolled in another trial of an investigational drug or device

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
treatment	Lemborexant 25 mg	20 participants will be randomized to take lemborexant 25mg at h.s for two consecutive nights
placebo	Placebo	10 participants will be randomized to take placebo at h.s. for two consecutive nights.

Primary Outcome Measures

Name	Time	Method
Change in CNS tau phosphorylation	48 hours	Changes in CSF pT181/T181 ratio compared to placebo

Secondary Outcome Measures

Name	Time	Method
Changes in other CSF AD biomarkers	48 hours	Changes in CSF pS202/S202, pT217/T217, and amyloid-beta

Trial Locations

Locations (1)

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States